GlycoMimetics to acquire Crescent Biopharma.

GlycoMimetics, a late clinical-stage biotechnology company, agreed to acquire Crescent Biopharma, a biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Financial terms were not disclosed. “Crescent was founded to harness recent breakthroughs in immuno-oncology and antibody-drug conjugates that pave the way for a next generation of therapies for patients with solid tumors,” Jonathan Violin, Crescent CEO.